Drug Profile
Ocriplasmin - Oxurion
Alternative Names: A-01016; Jejetrea®; Jetrea; Microplasmin; Recombinant human microplasmin; Recombinant microplasmin; THR-409Latest Information Update: 22 Jan 2021
Price :
$50
*
At a glance
- Originator University of Leuven
- Developer Alcon; Oxurion; ThromboGenics; University of Leuven
- Class Anti-ischaemics; Eye disorder therapies; Peptide fragments; Serine endopeptidases
- Mechanism of Action Antiplasmin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Thrombosis
Highest Development Phases
- Marketed Retinal disorders
- Phase II Diabetic retinopathy
- Suspended Deep vein thrombosis; Peripheral arterial occlusive disorders; Stroke
- No development reported Retinal vein occlusion
- Discontinued Age-related macular degeneration; Diabetic macular oedema
Most Recent Events
- 05 Jan 2021 ThromboGenics and Wagner Macula and Retina Center terminates the phase II TOTEM trial for Retinal disorders (Vitreomacular traction) in USA (Intravitreous) (NCT04300881)
- 12 Mar 2020 Ocriplasmin licensed to Inceptua Medicine worldwide for commercialisation
- 04 Oct 2019 ThromboGenics and Wagner Macula and Retina Center initiates enrolment in the phase II TOTEM trial for Retinal disorders (Vitreomacular traction) in USA (Intravitreous) (NCT04300881)